糖皮质激素作为急性呼吸窘迫综合征晚期挽救治疗的随机试验探索性再分析
该研究是对急性呼吸窘迫综合征网络随机对照试验的回顾性意向性治疗再分析,比较甲泼尼龙(2 mg/kg/d)与安慰剂(89例 vs 91例)在急性呼吸窘迫综合征晚期患者中的疗效与停药后事件。至第28天,甲泼尼龙组成功拔管率更高(71.9% vs 49.5%,RR 1.45,95%CI 1.14-1.85),拔管时间更短(HR 2.05,95%CI 1.42-2.96),ICU存活出院率更高(65.2% vs 48.3%,RR 1.35,95%CI 1.04-1.75),拔管前死亡更少(15.7% vs 25.3%,RR 0.62,95%CI 0.34-1.13)。停药后甲泼尼龙组重返机械通气更多(26.6% vs 6.7%,RR 3.98,95%CI 1.24-12.79)。作者认为拔管后快速停用糖皮质激素可能是疾病复发的原因,逐渐减量可能必要。
要点
- 至第28天,甲泼尼龙组成功拔管率71.9% vs 安慰剂组49.5%(RR 1.45,95%CI 1.14-1.85),拔管时间更短(HR 2.05,95%CI 1.42-2.96)。
- 甲泼尼龙组ICU存活出院率65.2% vs 安慰剂组48.3%(RR 1.35,95%CI 1.04-1.75)。
- 停药后甲泼尼龙组重返机械通气26.6% vs 安慰剂组6.7%(RR 3.98,95%CI 1.24-12.79)。
- 重返机械通气且未重新启用甲泼尼龙的患者呼吸机依赖和死亡风险增加。
- 尽管早期获益丧失,甲泼尼龙在所有次要结局和严重并发症(休克和严重感染)减少方面仍有大幅且显著的改善。
适用人群与场景
- 急性呼吸窘迫综合征晚期患者,随机接受甲泼尼龙(2 mg/kg/d)或安慰剂(89例 vs 91例),为多中心随机对照试验的回顾性意向性治疗再分析。
处置流程与药物剂量
- 甲泼尼龙2 mg/kg/d,用于急性呼吸窘迫综合征晚期患者,与安慰剂对照。
- 作者认为拔管后快速停用糖皮质激素可能是疾病复发的原因,逐渐减量可能必要。
红旗征与不能漏的情况
- 停药后重返机械通气:甲泼尼龙组26.6% vs 安慰剂组6.7%(RR 3.98,95%CI 1.24-12.79),与肾上腺抑制状态下全身炎症 reconstituted 一致。
- 重返机械通气且未重新启用甲泼尼龙的患者呼吸机依赖和死亡风险增加。
研究设计与关键结果
- 研究类型:多中心随机对照试验的回顾性意向性治疗再分析;甲泼尼龙组89例 vs 安慰剂组91例;目标样本量事后减少,对乐观的50%死亡率降低提供80%把握度。
- 至第28天,拔管前死亡:甲泼尼龙组15.7% vs 安慰剂组25.3%(RR 0.62,95%CI 0.34-1.13)。
- 至第28天,成功拔管:甲泼尼龙组71.9% vs 安慰剂组49.5%(RR 1.45,95%CI 1.14-1.85)。
- 成功拔管时间:甲泼尼龙组 vs 安慰剂组 HR 2.05(95%CI 1.42-2.96)。
- ICU存活出院:甲泼尼龙组65.2% vs 安慰剂组48.3%(RR 1.35,95%CI 1.04-1.75)。
- 治疗停止后重返机械通气:甲泼尼龙组26.6% vs 安慰剂组6.7%(RR 3.98,95%CI 1.24-12.79)。
- 重返机械通气且未重新启用甲泼尼龙的患者呼吸机依赖和死亡风险增加;尽管早期获益丧失,甲泼尼龙在所有次要结局和严重并发症(休克和严重感染)减少方面仍有大幅且显著的改善。
证据类型、等级与局限
- 证据类型:多中心随机对照试验的回顾性意向性治疗再分析。
- 目标样本量事后减少,对乐观的50%死亡率降低提供80%把握度。
- 局限:原文未报告局限性。
对床旁实践的改变
- 甲泼尼龙在积极治疗期间安全有效,可实现疾病缓解。
- 作者认为拔管后快速停用糖皮质激素可能是疾病复发的原因,逐渐减量可能必要以保留甲泼尼龙治疗期间获得的显著改善。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: In the Acute Respiratory Distress Syndrome Network randomized controlled trial, methylprednisolone treatment was associated with increased return to mechanical ventilation with partial loss of early improvements. We hypothesize a causal relationship between protocol-driven rapid discontinuation of methylprednisolone post extubation and return to mechanical ventilation. To explore this possibility, we investigated the timing that events occurred in each treatment arm during active treatment intervention (efficacy) and after stopping therapy.
DESIGN AND SETTINGS: Retrospective intention-to-treat analysis of multicenter randomized controlled trial.
PATIENTS AND INTERVENTIONS: Patients were randomized to methylprednisolone (2 mg/kg/d) or placebo (89 vs 91). The target sample size was reduced post hoc and provided 80% power for an optimistic 50% mortality reduction.
MEASUREMENTS AND MAIN RESULTS: Findings are reported as methylprednisolone versus placebo. By day 28, fewer patients died before achieving extubation (15.7% vs 25.3% and risk ratio, 0.62; 95% CI, 0.34-1.13), more achieved successful extubation (71.9% vs 49.5% and risk ratio, 1.45; CI, 1.14-1.85), time to successful extubation was shorter (hazard ratio, 2.05; CI, 1.42-2.96), and more were discharged alive from the ICU (65.2% vs 48.3%; risk ratio, 1.35; CI, 1.04-1.75). After treatment discontinuation, more methylprednisolone-treated patients returned to mechanical ventilation (26.6% vs 6.7%; risk ratio, 3.98; CI, 1.24-12.79)-consistent with reconstituted systemic inflammation in the presence of adrenal suppression. Participants returning to mechanical ventilation without reinstitution of methylprednisolone had increased risk of ventilator dependence and mortality. Despite loss of early benefits, methylprednisolone was associated with sizable and significant improvements in all secondary outcomes and reduction in serious complications (shock and severe infections).
CONCLUSIONS: During active intervention, methylprednisolone was safe and effective in achieving disease resolution. Our findings support rapid glucocorticoid discontinuation post extubation as likely cause of disease relapse. Gradual tapering might be necessary to preserve the significant improvements achieved during methylprednisolone administration.
参考来源
- Meduri GU, Bridges L, Siemieniuk RAC, et al. An Exploratory Reanalysis of the Randomized Trial on Efficacy of Corticosteroids as Rescue Therapy for the Late Phase of Acute Respiratory Distress Syndrome. Crit Care Med. 2018. PMID: 29432350. doi:10.1097/CCM.0000000000003021
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。